Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab plus steroids with rapid versus slow steroid tapering in AQP4-IgG-positive NMOSD
ChiCTR2400087203Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Proportion of patients without recurrence, Annualized relapse rate and 4 more. Started Jul 2024; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2400087203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087203.